- Home
- AMSC vs CELC Comparison
AMSC vs CELC Comparison
Compare AMSC & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMSC
- CELC
- Stock Information
- Founded
- AMSC 1987
- CELC 2011
- Country
- AMSC United States
- CELC United States
- Employees
- AMSC N/A
- CELC N/A
- Industry
- AMSC Metal Fabrications
- CELC Medical Specialities
- Sector
- AMSC Consumer Discretionary
- CELC Health Care
- Exchange
- AMSC Nasdaq
- CELC Nasdaq
- Market Cap
- AMSC 2.6B
- CELC 2.3B
- IPO Year
- AMSC 1991
- CELC 2017
- Fundamental
- Price
- AMSC $60.49
- CELC $54.60
- Analyst Decision
- AMSC Strong Buy
- CELC Strong Buy
- Analyst Count
- AMSC 2
- CELC 5
- Target Price
- AMSC $34.00
- CELC $53.60
- AVG Volume (30 Days)
- AMSC 927.0K
- CELC 888.2K
- Earning Date
- AMSC 10-29-2025
- CELC 11-13-2025
- Dividend Yield
- AMSC N/A
- CELC N/A
- EPS Growth
- AMSC N/A
- CELC N/A
- EPS
- AMSC 0.39
- CELC N/A
- Revenue
- AMSC $254,886,000.00
- CELC N/A
- Revenue This Year
- AMSC $28.23
- CELC N/A
- Revenue Next Year
- AMSC $11.78
- CELC N/A
- P/E Ratio
- AMSC $153.16
- CELC N/A
- Revenue Growth
- AMSC 63.73
- CELC N/A
- 52 Week Low
- AMSC $13.98
- CELC $7.58
- 52 Week High
- AMSC $61.00
- CELC $63.06
- Technical
- Relative Strength Index (RSI)
- AMSC 72.13
- CELC 57.48
- Support Level
- AMSC $54.89
- CELC $52.90
- Resistance Level
- AMSC $57.30
- CELC $63.06
- Average True Range (ATR)
- AMSC 2.82
- CELC 3.26
- MACD
- AMSC 0.77
- CELC -1.17
- Stochastic Oscillator
- AMSC 95.77
- CELC 32.96
About AMSC American Superconductor Corporation
American Superconductor Corp generates the ideas, technologies, and solutions that meet the world's demand for smarter, cleaner, and energy. Through its Windtec Solutions, the company enables manufacturers to launch wind turbines quickly, effectively, and profitably. Through its Gridtec Solutions, the company provides engineering planning services and grid systems that optimize network reliability, efficiency, and performance. The company's segment includes Grid and Wind. It generates maximum revenue from the Grid segment.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.